LeMaitre Vascular, Inc. (NASDAQ:LMAT) CEO George W. Lemaitre sold 10,000 shares of the business’s stock in a transaction on Monday, August 7th. The shares were sold at an average price of $33.62, for a total transaction of $336,200.00. Following the completion of the transaction, the chief executive officer now owns 3,436,808 shares of the company’s stock, valued at $115,545,484.96. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website.
Shares of LeMaitre Vascular, Inc. (NASDAQ:LMAT) traded down 1.47% during midday trading on Wednesday, reaching $33.56. 143,476 shares of the company traded hands. LeMaitre Vascular, Inc. has a 1-year low of $16.80 and a 1-year high of $36.09. The stock has a market capitalization of $631.43 million, a P/E ratio of 47.94 and a beta of 0.65. The stock’s 50-day moving average is $30.31 and its 200-day moving average is $27.02.
LeMaitre Vascular (NASDAQ:LMAT) last released its earnings results on Thursday, July 27th. The medical instruments supplier reported $0.23 EPS for the quarter, beating analysts’ consensus estimates of $0.17 by $0.06. LeMaitre Vascular had a return on equity of 15.02% and a net margin of 14.19%. The company had revenue of $25.80 million during the quarter, compared to the consensus estimate of $25.42 million. During the same quarter last year, the company earned $0.14 earnings per share. LeMaitre Vascular’s quarterly revenue was up 15.2% compared to the same quarter last year. Equities analysts predict that LeMaitre Vascular, Inc. will post $0.80 EPS for the current fiscal year.
The firm also recently announced a quarterly dividend, which will be paid on Thursday, September 7th. Shareholders of record on Wednesday, August 23rd will be issued a $0.055 dividend. This represents a $0.22 dividend on an annualized basis and a yield of 0.66%. The ex-dividend date of this dividend is Monday, August 21st. LeMaitre Vascular’s dividend payout ratio (DPR) is currently 31.88%.
LeMaitre Vascular declared that its board has initiated a stock repurchase program on Thursday, July 27th that permits the company to buyback $7.50 million in shares. This buyback authorization permits the medical instruments supplier to reacquire up to 1.4% of its shares through open market purchases. Shares buyback programs are often a sign that the company’s leadership believes its stock is undervalued.
COPYRIGHT VIOLATION NOTICE: This story was originally posted by Sports Perspectives and is owned by of Sports Perspectives. If you are accessing this story on another site, it was stolen and republished in violation of U.S. & international copyright legislation. The legal version of this story can be read at https://sportsperspectives.com/2017/08/09/insider-selling-lemaitre-vascular-inc-nasdaqlmat-ceo-sells-10000-shares-of-stock.html.
Several equities research analysts recently commented on LMAT shares. Zacks Investment Research raised shares of LeMaitre Vascular from a “hold” rating to a “buy” rating and set a $36.00 price target for the company in a report on Friday, April 28th. Stifel Nicolaus boosted their price target on shares of LeMaitre Vascular from $25.00 to $29.00 and gave the stock a “buy” rating in a report on Friday, April 28th. Canaccord Genuity reissued a “buy” rating and issued a $28.00 price target on shares of LeMaitre Vascular in a report on Thursday, April 27th. Benchmark Co. raised shares of LeMaitre Vascular from a “hold” rating to a “buy” rating in a report on Friday, July 28th. Finally, BidaskClub lowered shares of LeMaitre Vascular from a “strong-buy” rating to a “buy” rating in a report on Tuesday, July 25th. Four investment analysts have rated the stock with a hold rating and five have given a buy rating to the company. The company has a consensus rating of “Buy” and a consensus price target of $30.17.
Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Alps Advisors Inc. increased its position in LeMaitre Vascular by 0.3% in the second quarter. Alps Advisors Inc. now owns 20,947 shares of the medical instruments supplier’s stock valued at $654,000 after buying an additional 54 shares during the period. Bank of America Corp DE increased its position in LeMaitre Vascular by 0.3% in the first quarter. Bank of America Corp DE now owns 193,651 shares of the medical instruments supplier’s stock valued at $4,770,000 after buying an additional 536 shares during the period. American International Group Inc. increased its position in LeMaitre Vascular by 7.0% in the first quarter. American International Group Inc. now owns 8,310 shares of the medical instruments supplier’s stock valued at $205,000 after buying an additional 545 shares during the period. Blair William & Co. IL increased its position in LeMaitre Vascular by 6.9% in the first quarter. Blair William & Co. IL now owns 11,977 shares of the medical instruments supplier’s stock valued at $295,000 after buying an additional 768 shares during the period. Finally, Bank of New York Mellon Corp increased its position in LeMaitre Vascular by 1.6% in the first quarter. Bank of New York Mellon Corp now owns 88,552 shares of the medical instruments supplier’s stock valued at $2,181,000 after buying an additional 1,408 shares during the period. 67.10% of the stock is owned by institutional investors and hedge funds.
LeMaitre Vascular Company Profile
LeMaitre Vascular, Inc is a provider of medical devices for the treatment of peripheral vascular disease. The Company develops, manufactures and markets medical devices and implants used primarily in the field of vascular surgery. It is engaged in the design, marketing, sales and technical support of medical devices and implants for the treatment of peripheral vascular disease industry segment.
Receive News & Ratings for LeMaitre Vascular Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LeMaitre Vascular Inc. and related companies with MarketBeat.com's FREE daily email newsletter.